Novel and emerging treatments for major depression

[1]  S. Zisook,et al.  Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. , 2022, The New England journal of medicine.

[2]  Richard E. Daws,et al.  Increased global integration in the brain after psilocybin therapy for depression , 2022, Nature Medicine.

[3]  N. Koutsouleris,et al.  The potential of precision psychiatry: what is in reach? , 2022, The British Journal of Psychiatry.

[4]  John A. Williams,et al.  Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders , 2022, JAMA psychiatry.

[5]  Lewis W. Paton,et al.  Predicting relapse or recurrence of depression: systematic review of prognostic models , 2022, The British Journal of Psychiatry.

[6]  Á. Pascual-Leone,et al.  Transcranial magnetic stimulation (TMS) for geriatric depression , 2021, Ageing Research Reviews.

[7]  M. Fava,et al.  REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. , 2021, The American journal of psychiatry.

[8]  W. van den Brink,et al.  Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review , 2021, Psychopharmacology.

[9]  T. M. Lima,et al.  Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses , 2021, European Journal of Clinical Pharmacology.

[10]  N. Freemantle,et al.  Maintenance or Discontinuation of Antidepressants in Primary Care. , 2021, The New England journal of medicine.

[11]  Bin Zhang,et al.  Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. , 2021, Journal of affective disorders.

[12]  M. Buoli,et al.  Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review , 2021, International journal of molecular sciences.

[13]  M. Nettis.  Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders , 2021, Brain, behavior, & immunity - health.

[14]  G. Martinotti,et al.  Hypomanic/manic switch after transcranial magnetic stimulation in mood disorders: A systematic review and meta-analysis , 2021, World journal of psychiatry.

[15]  Michael Alfonso,et al.  Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review , 2021, Cureus.

[16]  S. Stahl,et al.  REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study , 2021, Frontiers in Pharmacology.

[17]  D. Nutt,et al.  Trial of Psilocybin versus Escitalopram for Depression. , 2021, The New England journal of medicine.

[18]  James D. Griffith,et al.  Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis , 2021, Psychopharmacology.

[19]  M. Bloch,et al.  Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. , 2021, The American journal of psychiatry.

[20]  G. Dawson,et al.  The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial , 2021, Neuropsychopharmacology.

[21]  Paulo J C Suen,et al.  Determinants of sham response in tDCS depression trials: a systematic review and meta-analysis , 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  J. Murrough,et al.  Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date , 2021, Drug design, development and therapy.

[23]  R. McIntyre,et al.  Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials , 2021, Expert opinion on emerging drugs.

[24]  H. Lee,et al.  Repetitive transcranial magnetic stimulation treatment for peripartum depression: systematic review & meta-analysis , 2020, BMC Pregnancy and Childbirth.

[25]  Cheng-Ta Li,et al.  Efficacy and tolerability of theta-burst stimulation for major depression: A systematic review and meta-analysis , 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression: A Health Technology Assessment. , 2021, Ontario health technology assessment series.

[27]  P. Fitzgerald,et al.  Efficacy, efficiency and safety of high-frequency repetitive transcranial magnetic stimulation applied more than once a day in depression: A systematic review. , 2020, Journal of affective disorders.

[28]  R. Schoevers,et al.  Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review. , 2020, Journal of affective disorders.

[29]  S. Marwaha,et al.  Repetitive Transcranial Magnetic Stimulation in the Treatment of Bipolar Disorder , 2020, Therapeutic advances in psychopharmacology.

[30]  Matthew W. Johnson,et al.  Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder , 2020, JAMA psychiatry.

[31]  D. Iosifescu,et al.  P.327 Efficacy and safety of AXS-05, an oral, NMDA receptor antagonist with multimodal activity in major depressive disorder , 2020, European Neuropsychopharmacology.

[32]  D. Nutt,et al.  Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies , 2020, Acta psychiatrica Scandinavica.

[33]  Jack C. Rogers,et al.  Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression in Adolescence: A Systematic Review. , 2020, Journal of affective disorders.

[34]  M. Demitrack,et al.  Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial , 2020, Neuropsychopharmacology.

[35]  W. Marcantoni,et al.  A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. , 2020, Journal of affective disorders.

[36]  Aarti Gupta,et al.  A systematic review of ketamine for the treatment of depression among older adults , 2020, International Psychogeriatrics.

[37]  L. Bartova,et al.  Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment , 2020, The international journal of neuropsychopharmacology.

[38]  A. Young,et al.  Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis , 2020, International review of psychiatry.

[39]  C. Reid,et al.  Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. , 2020, JAMA psychiatry.

[40]  Hua Hu,et al.  Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials , 2020, General Psychiatry.

[41]  A. Young,et al.  Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. , 2020, The lancet. Psychiatry.

[42]  E. Sibille,et al.  Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders , 2020, Molecular Psychiatry.

[43]  A. Young,et al.  Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). , 2020, The Journal of clinical psychiatry.

[44]  C. Andrade,et al.  A pilot, open-label investigation of the efficacy of glucosamine for the treatment of major depression. , 2020, Asian journal of psychiatry.

[45]  F. Fregni,et al.  Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[46]  M. Jacobson,et al.  P.601 AXS-05 (dextromethorphan/bupropion), a novel, oral, investigational agent for major depressive disorder: Results of a randomized, double-blind, active-controlled, multi-center trial (ASCEND) , 2019, European Neuropsychopharmacology.

[47]  Yang Ma,et al.  Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[48]  W. Drevets,et al.  Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[49]  A. Ravindran,et al.  Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. , 2019, Journal of affective disorders.

[50]  R. Shelton,et al.  A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). , 2019, The Journal of clinical psychiatry.

[51]  P. Fitzgerald,et al.  Potential predictors of depressive relapse following repetitive Transcranial Magnetic Stimulation: A systematic review. , 2019, Journal of affective disorders.

[52]  Xiang Li,et al.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. , 2019, JAMA psychiatry.

[53]  S. Dursun,et al.  Esketamine for treatment-resistant depression , 2020, Drug and Therapeutics Bulletin.

[54]  M. Fava,et al.  Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) , 2019, The international journal of neuropsychopharmacology.

[55]  R. Horton,et al.  Reducing the global burden of depression: a Lancet–World Psychiatric Association Commission , 2019, The Lancet.

[56]  A. Ganho-Ávila,et al.  Efficacy of rTMS in decreasing postnatal depression symptoms: A systematic review , 2019, Psychiatry Research.

[57]  D. Nutt.  Psychedelic drugs—a new era in
psychiatry?
 , 2019, Dialogues in clinical neuroscience.

[58]  R. Shelton,et al.  Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.

[59]  O. Mors,et al.  Efficacy of anti‐inflammatory treatment on major depressive disorder or depressive symptoms: meta‐analysis of clinical trials , 2019, Acta psychiatrica Scandinavica.

[60]  A. Young,et al.  Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis , 2019, BMJ.

[61]  P. Croarkin,et al.  Accelerated TMS for Depression: A systematic review and meta-analysis , 2019, Psychiatry Research.

[62]  Á. Pascual-Leone,et al.  Durability of antidepressant response to repetitive transcranial magnetic stimulation: Systematic review and meta-analysis , 2019, Brain Stimulation.

[63]  Paolo Cassano,et al.  Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms. , 2019, Journal of affective disorders.

[64]  Robin L. Carhart-Harris,et al.  How do psychedelics work? , 2019, Current opinion in psychiatry.

[65]  Peter B. Jones,et al.  The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial , 2018, The lancet. Psychiatry.

[66]  D. Rubinow,et al.  Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials , 2018, The Lancet.

[67]  J. Ioannidis,et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.

[68]  F. Fregni,et al.  A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[69]  P. Xie,et al.  A systematic review and meta-analysis of deep brain stimulation in treatment-resistant depression , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[70]  D. Araujo,et al.  Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial , 2018, Psychological Medicine.

[71]  C. Loo,et al.  Side-effects associated with ketamine use in depression: a systematic review. , 2018, The lancet. Psychiatry.

[72]  D. Nutt,et al.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up , 2017, Psychopharmacology.

[73]  P. Mitchell,et al.  Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[74]  D. Rubinow,et al.  Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial , 2017, The Lancet.

[75]  S. Traynelis,et al.  Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. , 2016, Pharmacology & therapeutics.

[76]  L. Monteggia,et al.  BDNF – a key transducer of antidepressant effects , 2016, Neuropharmacology.

[77]  G. Aghajanian,et al.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants , 2016, Nature Medicine.

[78]  J. Riba,et al.  Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study , 2016, Journal of clinical psychopharmacology.

[79]  D. Kondziolka,et al.  A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression , 2015, Biological Psychiatry.

[80]  Suresh D. Muthukumaraswamy,et al.  Marked Reductions in Visual Evoked Responses But Not γ-Aminobutyric Acid Concentrations or γ-Band Measures in Remitted Depression , 2013, Biological Psychiatry.

[81]  D. Pine,et al.  Depression in adolescence , 2012, The Lancet.

[82]  G. Sanacora,et al.  Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders , 2012, Neuropharmacology.

[83]  M. Pinquart,et al.  Depression and cancer mortality: a meta-analysis , 2010, Psychological Medicine.

[84]  J. Price,et al.  Neurocircuitry of Mood Disorders , 2010, Neuropsychopharmacology.

[85]  P. Cowen,et al.  Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines , 2008, Journal of psychopharmacology.

[86]  H. Kuper,et al.  Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. , 2006, European heart journal.

[87]  D. Kleinbaum,et al.  Depressive symptoms during childhood and adult obesity: the Zurich Cohort Study , 2005, Molecular Psychiatry.

[88]  W. Wagner,et al.  Über die Hemmwirkung einiger Amine auf das Wachstum von Tuberkelbazillen , 2004, SCIENCE NATURE.